News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Oil jumps over 3% after Iran says the Strait of Hormuz is closed, lifting the dollar and pressuring global markets.
  • U.S. futures and Asian equities slip as Middle East strikes and Strait uncertainty raise risk ahead of heavy Q2 earnings.
  • Wolfe Research warns H2 2026 congressional deadlines, tariff shifts and regulatory rulemakings could materially affect manufacturing, financials and energy.
  • EU foreign ministers will discuss trade restrictions on West Bank settlements, but deep divisions make a decisive vote unlikely.
  • Australia's ASIC fined Deutsche Bank A$2 million for widespread misreporting of OTC derivatives between Oct 2024 and Aug 2025.
  • Similarweb signals early LLM contract wins could re-accelerate revenue and support a stock recovery if proofs convert to paid deals.

Latest Articles

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Inc., a Nasdaq-listed biotechnology company specializing in regenerative tissue therapies, announced five key leadership appointments including additions to its Board of Directors and the naming of a new Chief Commercial Officer. These leadership enhancements aim to strengthen the company's commercial and strategic capabilities as …

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics announced plans to initiate a Phase 2a proof-of-concept clinical trial for its drug candidate CAD-1005, targeting prevention of Acute Kidney Injury (AKI) associated with cardiac surgery (CSA-AKI). This expands the potential application of CAD-1005, which is already in late-stage development for heparin-induced thrombocytopenia…

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum Ltd. announced a major production milestone as one of the largest U.S.-based interconnect manufacturers adopted QTREX's Additively Manufactured Electronics (AME) technology for full production after extensive validation, achieving a 97% yield rate. This advancement marks QTREX's readiness for demanding manufacturing environments and s…

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology has secured a strategic advisory engagement from a leading global tax and financial advisory firm to support the expansion of its India-based Global Capability Center (GCC) in a Tier-II city. This reflects a growing corporate trend of expanding GCCs beyond traditional metro areas to leverage deeper talent pools and improved operat…

Leadership Shake-Up Sends Fiserv Shares Lower as CEO Departs for Truist

Leadership Shake-Up Sends Fiserv Shares Lower as CEO Departs for Truist

Fiserv Inc. shares fell about 7% after CEO Mike Lyons announced he is leaving to assume the CEO role at Truist Financial Corporation. The payments and financial-technology firm appointed Takis Georgakopoulos as CEO effective immediately. Fiserv also reaffirmed its full-year 2026 outlook, maintaining expectations for modest organic revenue growth an…

Nvidia Moves to Issue at Least $20 Billion of Investment-Grade Debt

Nvidia Moves to Issue at Least $20 Billion of Investment-Grade Debt

Nvidia Corp. is preparing an investment-grade bond offering intended to raise a minimum of $20 billion. The sale spans seven maturities between two and 30 years, with the longest-dated tranche marketed around 0.9 percentage points over Treasuries. Proceeds are slated for general corporate purposes, including repayment and refinancing of existing no…

Strategy Inc. Sells $209M of Stock, Deploys Proceeds to Buy 1,587 Bitcoin

Strategy Inc. Sells $209M of Stock, Deploys Proceeds to Buy 1,587 Bitcoin

Strategy Inc. sold 1,732,553 shares under its at-the-market (ATM) offering last week, generating $209.0 million in net proceeds. The company used the proceeds to acquire 1,587 bitcoin between June 8 and June 14, spending $100.0 million including fees at an average price of $63,024 per bitcoin. Strategy now holds 846,842 bitcoin purchased for a tota…

TSX Futures Tick Up as Gold Rallies After U.S.-Iran Interim Peace Accord

TSX Futures Tick Up as Gold Rallies After U.S.-Iran Interim Peace Accord

Futures tied to Canada’s main equity gauge rose Monday, supported by a jump in gold prices after Pakistan said the United States and Iran reached a preliminary agreement to halt hostilities. The Canadian benchmark's futures gained, U.S. futures rose following tech-led rallies overseas, and markets responded to signs that the conflict may de-escalat…

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon Ltd. announced a collaboration with a leading European medical center and a clinical research organization to conduct a human study evaluating the nasal residence time of its investigational NASARIX™ (PL-14) Allergy Blocker. This study aims to characterize the formulation's retention in the nasal cavity, aiding in quantifying the duration…

Fiserv Announces Leadership Transition

Fiserv Announces Leadership Transition

Fiserv, a global leader in payments and financial services technology, has announced Takis Georgakopoulos as its new CEO following Mike Lyons' departure to Truist Financial. Georgakopoulos brings extensive experience in payments, technology, AI, and cybersecurity. The company reaffirms its 2026 outlook with expected organic revenue growth of 1-3% a…

GPGI Executive Knott Acquires Nearly $1M in Shares Amid Stock Volatility

GPGI Executive Knott Acquires Nearly $1M in Shares Amid Stock Volatility

Thomas R. Knott, Principal Executive Officer and Chief Investment Officer at GPGI, Inc. (NASDAQ:GPGI), acquired 85,250 shares of the company's Class A Common Stock on June 11, 2026, according to a Securities and Exchange Commission filing. The transaction, valued at $994,867, occurred as shares traded between $11.36 and $11.87. This purchase brings…

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 trials of navacaprant for major depressive disorder failed to meet primary and key secondary endpoints. The company will cease development of navacaprant and realign its resources to advance other pipeline programs in Alzheimer's disease agitation, schizophrenia, and cardiometabolic d…

AFC Announces Dividend for the Second Quarter 2026

AFC Announces Dividend for the Second Quarter 2026

Advanced Flower Capital Inc. announced a quarterly dividend of $0.05 per share for the quarter ending June 30, 2026, payable on July 15, 2026. This dividend matches the payout from the prior quarter, reflecting steady dividend policy from the business development company which provides credit solutions to lower middle-market companies.